Fennec Pharmaceuticals Stock Fundamentals
| FENC Stock | USD 6.45 0.15 2.27% |
Fennec Pharmaceuticals fundamentals help investors to digest information that contributes to Fennec Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Fennec Stock. The fundamental analysis module provides a way to measure Fennec Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fennec Pharmaceuticals stock.
At present, Fennec Pharmaceuticals' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 24.2 M, whereas Net Loss is projected to grow to (17.3 M).
Fennec | Select Account or Indicator |
Fennec Pharmaceuticals Company Profit Margin Analysis
Fennec Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Fennec Pharmaceuticals Profit Margin | (0) % |
Most of Fennec Pharmaceuticals' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fennec Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Fennec Pretax Profit Margin
Pretax Profit Margin |
|
At present, Fennec Pharmaceuticals' Pretax Profit Margin is projected to increase significantly based on the last few years of reporting.
Based on the latest financial disclosure, Fennec Pharmaceuticals has a Profit Margin of -0.0015%. This is 99.99% lower than that of the Biotechnology sector and 99.99% lower than that of the Health Care industry. The profit margin for all United States stocks is 99.88% lower than that of the firm.
Fennec Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Fennec Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Fennec Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Fennec Pharmaceuticals competition to find correlations between indicators driving Fennec Pharmaceuticals's intrinsic value. More Info.Fennec Pharmaceuticals is rated below average in return on equity category among its peers. It is rated # 3 in return on asset category among its peers . At present, Fennec Pharmaceuticals' Return On Equity is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Fennec Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Fennec Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fennec Pharmaceuticals' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fennec Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Fennec Pharmaceuticals by comparing valuation metrics of similar companies.Fennec Pharmaceuticals is currently under evaluation in profit margin category among its peers.
Fennec Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fennec Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fennec Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Fennec Fundamentals
| Return On Equity | -10.06 | ||||
| Return On Asset | 0.0447 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 175.28 M | ||||
| Shares Outstanding | 27.29 M | ||||
| Shares Owned By Insiders | 16.20 % | ||||
| Shares Owned By Institutions | 58.61 % | ||||
| Number Of Shares Shorted | 2.04 M | ||||
| Price To Earning | (3.82) X | ||||
| Price To Book | 57.93 X | ||||
| Price To Sales | 3.84 X | ||||
| Revenue | 47.54 M | ||||
| Gross Profit | 44.35 M | ||||
| EBITDA | 3.6 M | ||||
| Net Income | (70 K) | ||||
| Cash And Equivalents | 14.91 M | ||||
| Cash Per Share | 0.57 X | ||||
| Total Debt | 19.59 M | ||||
| Debt To Equity | 0.58 % | ||||
| Current Ratio | 5.12 X | ||||
| Book Value Per Share | (0.20) X | ||||
| Cash Flow From Operations | (17.14 M) | ||||
| Short Ratio | 41.01 X | ||||
| Target Price | 12.6 | ||||
| Beta | 0.36 | ||||
| Market Capitalization | 182.33 M | ||||
| Total Asset | 44.95 M | ||||
| Retained Earnings | (219.31 M) | ||||
| Working Capital | 19.3 M | ||||
| Current Asset | 7.88 M | ||||
| Current Liabilities | 1.97 M | ||||
| Net Asset | 44.95 M |
About Fennec Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fennec Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fennec Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fennec Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -18.9 K | -18 K | |
| Total Revenue | 47.5 M | 49.9 M | |
| Cost Of Revenue | 3.2 M | 3.3 M | |
| Stock Based Compensation To Revenue | 0.29 | 0.28 | |
| Sales General And Administrative To Revenue | 0.48 | 0.46 | |
| Research And Ddevelopement To Revenue | 0.01 | 0.01 | |
| Revenue Per Share | 1.74 | 1.83 | |
| Ebit Per Revenue | 0.05 | 0.06 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Fennec Pharmaceuticals Piotroski F Score and Fennec Pharmaceuticals Altman Z Score analysis. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.